Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.61 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.61 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.61 |
| ▸ | MMP3 | P08254 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | CDC25B | P30305 | 1/20 | 0.53 |
| ▸ | PLK1 | P53350 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27813032 | 0.84 | NR4A1 (0.57) | NR4A1NR4A2NR4A3MMP3HDAC8 | |
| SCHEMBL10995822 | 0.84 | NR4A1 (0.57) | NR4A1NR4A2NR4A3MMP3HDAC8 | |
| SCHEMBL9480890 | 0.82 | NR4A1 (0.55) | NR4A1NR4A2NR4A3MMP3HDAC8 | |
| SCHEMBL9480896 | 0.82 | NR4A1 (0.55) | NR4A1NR4A2NR4A3MMP3HDAC8 | |
| SCHEMBL10407111 | 0.82 | NR4A1 (0.59) | NR4A1NR4A2NR4A3MMP3HDAC8 | |
| SCHEMBL29002838 | 0.82 | NR4A1 (0.59) | NR4A1NR4A2NR4A3MMP3HDAC8 | |
| SCHEMBL8376485 | 0.82 | NR4A1 (0.59) | NR4A1NR4A2NR4A3MMP3HDAC8 | |
| SCHEMBL9548533 | 0.79 | NR4A1 (0.60) | NR4A1NR4A2NR4A3MMP3HDAC8 | |
| SCHEMBL11323085 | 0.79 | NR4A1 (0.55) | NR4A1NR4A2NR4A3MMP3HDAC8 | |
| SCHEMBL7218991 | 0.78 | NR4A1 (0.71) | NR4A1NR4A2NR4A3MMP3HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263642-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | FIBROGEN, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2341904-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | Fibrogen, Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010024908-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | FIBROGEN, INC. (US) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263642-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS | PMP22, MAG, NEFM | NR4A1 3771/4885NR4A2 3438/4885NR4A3 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.